SOUTH JORDAN, Utah, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading
manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures,
particularly in cardiology, radiology and endoscopy, today announced that it has received 510(k) clearance for the SwiftNINJA™
Steerable Microcatheter. The clearance covers peripheral and coronary applications. With the exception of Japan, Merit has
global distribution rights for the SwiftNINJA.
“For the past several months we have been marketing this unique product with great success in Europe,” said Fred
P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “Physician response relating to range, convenience and overall
cost, when compared to the use of multiple devices, has validated our initial expectations.”
The SwiftNINJA is scheduled to be launched simultaneously with the Corvocet™ Biopsy System, which also received
510(k) clearance recently.
“We believe these two patented and transformative technologies will provide substantial momentum and enthusiasm
amongst our sales force and customers as we prepare for 2017,” Lampropoulos said.
ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable
medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy.
Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 200 individuals.
Merit employs approximately 4,100 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia;
Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway,
Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada, and Melbourne, Australia.
Statements contained in this release which are not purely historical, including, without limitation, statements
regarding Merit's forecasted plans, revenues, net income, financial results or anticipated or completed acquisitions, are
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and
uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2015. Such risks
and uncertainties include risks relating to Merit's potential inability to successfully manage growth through acquisitions,
including the inability to commercialize technology acquired through completed, proposed or future transactions (including the
recently completed acquisition of DFINE); product recalls and product liability claims; expenditures relating to research,
development, testing and regulatory approval or clearance of Merit's products and risks that such products may not be developed
successfully or approved for commercial use; governmental scrutiny and regulation of the medical device industry, including
governmental inquiries, investigations and proceedings involving Merit; reforms to the 510(k) process administered by the U.S. Food
and Drug Administration; restrictions on Merit's liquidity or business operations resulting from its current debt agreements;
infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; the potential of
fines, penalties or other adverse consequences if Merit's employees or agents violate the U.S. Foreign Corrupt Practices Act or
other laws or regulations; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant
adverse changes in governing regulations; changes in tax laws and regulations in the United States or other countries; increases in
the prices of commodity components; negative changes in economic and industry conditions in the United States or other countries;
termination or interruption of relationships with Merit's suppliers, or failure of such suppliers to perform; fluctuations in
exchange rates; concentration of a substantial portion of Merit's revenues among a few products and procedures; development
of new products and technology that could render Merit's existing products obsolete; market acceptance of new products; volatility
in the market price of Merit's common stock; modification or limitation of governmental or private insurance reimbursement
policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable
environmental laws; changes in key personnel; work stoppage or transportation risks; introduction of products in a timely
fashion; price and product competition; availability of labor and materials; fluctuations in and obsolescence of inventory; and
other factors referred to in Merit's Annual Report on Form 10-K for the year ended December 31, 2015 and other materials filed with
the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its
behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ
materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as
predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those
estimates.
Contact: Anne-Marie Wright, Vice President, Corporate Communications Phone: (801) 208-4167 e-mail: awright@merit.com Fax: (801) 253-1688
